Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma
S Falk, A Anthoney, M Eatock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
British Journal of Cancer
|
March 5, 2002
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
T R J Evans, K W Colston, F J Lofts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin
Ivo M Hennig, Jay D Naik, Sarah Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
C Twelves, K Hoekman, A Bowman, et al.
British Journal of Cancer
|
January 18, 2017
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
P S Hall, S R Lord, M Collinson, et al.
British Journal of Cancer
|
August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J W Valle, H Wasan, P Johnson, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, S Stacchiotti, et al.
Science Translational Medicine
|
June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
Robert A Adair, Victoria Roulstone, Karen J Scott, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma
S Falk, A Anthoney, M Eatock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
British Journal of Cancer
|
March 5, 2002
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
T R J Evans, K W Colston, F J Lofts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin
Ivo M Hennig, Jay D Naik, Sarah Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
C Twelves, K Hoekman, A Bowman, et al.
British Journal of Cancer
|
January 18, 2017
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
P S Hall, S R Lord, M Collinson, et al.
British Journal of Cancer
|
August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J W Valle, H Wasan, P Johnson, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, S Stacchiotti, et al.
Science Translational Medicine
|
June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
Robert A Adair, Victoria Roulstone, Karen J Scott, et al.
Page
of 4